[1] Westeneng H-J, Debray TPA, Visser AE, Van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and vali- dation of a personalised prediction model 2018;17:423.
[2] Mccauley ME, Baloh RH. Inflammation in ALS/FTD. Pathogenesis 2019;137: 715–30.
[3] Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol 1989;8:289–94.
[4] Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyo- trophic lateral sclerosis. Arch Neurol 1993;50:30–6.
[5] Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001;57:1282–9.
[6] Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 2009;4:389–98.
[7] Boille´e S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and micro- glia. Science 2006;312:1389–92.
[8] Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011;11:775–87.
[9] Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med 2017;23:1018–27.
[10] Kabba JA, Xu Y, Christian H, Ruan W, Chenai K, Xiang Y, et al. Microglia: House- keeper of the Central Nervous System. Cell Mol Neurobiol 2018;38:53–71.
[11] Crain JM, Nikodemova M, Watters JJ. Microglia express distinct M1 and M2 phe- notypic markers in the postnatal and adult central nervous system in male and female mice. J Neurosci Res 2013;91:1143–51.
[12] Ransohoff RM. A polarizing question: Do M1 and M2 microglia exist. Nat Neurosci 2016;19:987–91.
[13] Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J Neuroinflammation 2014;11:98.
[14] Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji H-L, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 2016;7:e2062.
[15] Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuropro- tective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 2012;237:147–52.
[16] Zhang J, Liu Y, Liu X, Li S, Cheng C, Chen S, et al. Dynamic changes of CX3CL1/ CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model. Transl Neurodegener 2018;7:35.
[17] Terashima T, Kojima H, Urabe H, Yamakawa I, Ogawa N, Kawai H, et al. Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by pro- moting protective microglial migration. J Neurosci Res 2014;92:856–69.
[18] Terashima T, Kobashi S, Watanabe Y, Nakanishi M, Honda N, Katagi M, et al. Enhancing the Therapeutic Efficacy of Bone Marrow-Derived Mononuclear Cells with Growth Factor-Expressing Mesenchymal Stem Cells for ALS in Mice. IScience 2020;23:101764.
[19] Ohashi N, Terashima T, Katagi M, Nakae Y, Okano J, Suzuki Y, et al. GLT1 gene delivery based on bone marrow-derived cells ameliorates motor function and survival in a mouse model of. ALS. Sci Rep 2021;11:12803.
[20] Kobashi S, Terashima T, Katagi M, Nakae Y, Okano J, Suzuki Y, et al. Transplanta- tion of M2-Deviated Microglia Promotes Recovery of Motor Function after Spinal Cord Injury in Mice. Mol Ther 2020;28:254–65.
[21] Tamaki Y, Shodai A, Morimura T, Hikiami R, Minamiyama S, Ayaki T, et al. Elimi- nation of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfold- ing-specific intrabody with dual proteolytic signals. Sci Rep 2018;8:6030.
[22] Abati E, Bresolin N, Pietro Comi G, Corti S. Preconditioning and Cellular Engineer- ing to Increase the Survival of Transplanted Neural Stem Cells for Motor Neuron Disease Therapy. Mol Neurobiol 2019;56:3356–67.
[23] Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, et al. Focal transplan- tation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports 2014;3:242–9.
[24] Izrael M, Slutsky SG, Admoni T, Cohen L, Granit A, Hasson A, et al. Safety and effi- cacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models. Stem Cell Res Ther 2018;9:152.
[25] Abati E, Bresolin N, Comi G, Corti S. Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis. Mol Neurobiol 2019;56:6703–15.
[26] Rossi C, Cusimano M, Zambito M, Finardi A, Capotondo A, Garcia-Manteiga JM, et al. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis 2018;9:250.
[27] Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2006;103:16021–6.
[28] Papadeas ST, Kraig SE, O’Banion C, Lepore AC, Maragakis NJ. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neu- ron degeneration in vivo. Proc Natl Acad Sci U S A 2011;108:17803–8.
[29] Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci 2019;13:1310.
[30] Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease- Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 2018;173:1073–81.
[31] Zhu D, Yang N, Liu YY, Zheng J, Ji C, Zuo PP. M2 Macrophage Transplantation Ameliorates Cognitive Dysfunction in Amyloid-b-Treated Rats Through Regula- tion of Microglial Polarization. J Alzheimers Dis 2016;52:483–95.
[32] Kanazawa M, Miura M, Toriyabe M, Koyama M, Hatakeyama M, Ishikawa M, et al. Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats. Sci Rep 2017;7:42582.
[33] Mazzini L, Gelati M, Profico DC, Soraru` G, Ferrari D, Copetti M, et al. Results from
Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotro- phic Lateral Sclerosis: A Long-Term Outcome. Stem Cells Transl Med 2019;8: 887–97.
[34] Dello Russo C, Cappoli N, Coletta I, Mezzogori D, Paciello F, Pozzoli G, et al. The human microglial HMC3 cell line: where do we stand? A systematic literature review. J Neuroinflammation 2018;15:259.
[35] Chu D-T, Phuong TNT, Tien NLB, Tran DK, Van Thanh V, Quang TL, et al. An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells. Int J Mol Sci 2020;21:708.
[36] Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of micro- glia. Front Cell Neurosci 2013;7:45.
[37] Corti S, Locatelli F, Donadoni C, Guglieri M, Papadimitriou D, Strazzer S, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 2004;127:2518– 32.
[38] Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002;23:403–8.
[39] Lee SC, Liu W, Brosnan CF, Dickson DW. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia 1994;12:309–18.
[40] Boche D, Perry VH, Nicoll JAR. Review: Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 2013;39:3–18.
[41] Pepe G, De Maglie M, Minoli L, Villa A, Maggi A, Vegeto E. Selective proliferative response of microglia to alternative polarization signals. J Neuroinflammation 2017;14:236.
[42] Gluckman JC, Canque B, Chapuis F, Rosenzwajg M. In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther 1997;3:187–96.
論文の公開元へ
